Below is Validea's guru fundamental report for EQUIFAX INC (EFX). Of the 22 guru strategies we follow, EFX rates highest using our P/B Growth Investor model based on the published strategy of ...

Barclays analyst Manav Patnaik maintained a Buy rating on Equifax (EFX – Research Report) today and set a price target of $325.00. The company’s shares closed yesterday at $250.87. Leverage ...

In a report released today, Arthur Truslove from Citi maintained a Buy rating on Equifax (EFX – Research Report), with a price target of $289.00. The company’s shares closed last Friday at ...

2025 Free Cash Flow Guidance: About $900 million, with cash conversion at about 95%. Equifax Inc (NYSE:EFX) achieved a strong financial performance in 2024, with revenue up almost 8% and adjusted ...

In this article, I noted that the company did well when it reported results from its 96-week phase 2b HARMONY study using its drug Efruxifermin [EFX] for pre-cirrhotic Metabolic dysfunction ...

In trading on Thursday, shares of Equifax Inc (Symbol: EFX) crossed below their 200 day moving average of $263.93, changing hands as low as $251.60 per share. Equifax Inc shares are currently ...

The phase 2b trial of efruxifermin (EFX) missed its primary endpoint in 2023. However, while the FGF21 analog was no better than placebo after 36 weeks, Akero argued that deepening effects on ...

Among patients with baseline and week 96 biopsies (n=134), 39% of patients treated with 50mg EFX (n=46) experienced reversal of cirrhosis with no worsening of MASH, representing a 24% effect size ...

Amritapuri , Kollam conducted the ASME EFx, a spectacular technical fest that brought together over 300 participants from across South India, with ASME faculty coordinator Dr Karthik V Shankar , ...

ATLANTA, Feb. 5, 2025 /PRNewswire/ -- Equifax® (NYSE: EFX) today announced that the Equifax Board of Directors declared a quarterly dividend of $0.39 per share, payable on March 14, 2025, to ...